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Christa L Fischer Walker* and Neff WalkerAbstract
Background: Diarrhea is a leading cause of morbidity and mortality among children under five years of age. The
Lives Saved Tool (LiST) is a model used to calculate deaths averted or lives saved by past interventions and for the
purposes of program planning when costly and time consuming impact studies are not possible.
Discussion: LiST models the relationship between coverage of interventions and outputs, such as stunting, diarrhea
incidence and diarrhea mortality. Each intervention directly prevents a proportion of diarrhea deaths such that the
effect size of the intervention is multiplied by coverage to calculate lives saved. That is, the maximum effect size
could be achieved at 100% coverage, but at 50% coverage only 50% of possible deaths are prevented. Diarrhea
mortality is one of the most complex causes of death to be modeled. The complexity is driven by the combination
of direct prevention and treatment interventions as well as interventions that operate indirectly via the reduction in
risk factors, such as stunting and wasting. Published evidence is used to quantify the effect sizes for each direct and
indirect relationship. Several studies have compared measured changes in mortality to LiST estimates of mortality
change looking at different sets of interventions in different countries. While comparison work has generally found
good agreement between the LiST estimates and measured mortality reduction, where data availability is weak, the
model is less likely to produce accurate results. LiST can be used as a component of program evaluation, but should
be coupled with more complete information on inputs, processes and outputs, not just outcomes and impact.
Summary: LiST is an effective tool for modeling diarrhea mortality and can be a useful alternative to large and
expensive mortality impact studies. Predicting the impact of interventions or comparing the impact of more than
one intervention without having to wait for the results of large and expensive mortality studies is critical to keep
programs focused and results oriented for continued reductions in diarrhea and all-cause mortality among children
under five years of age.
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Diarrhea is a leading cause of morbidity and mortality
among children under five years of age around the world
[1]. Preventing and treating infectious diarrhea does not
require expensive or technologically complex interven-
tions; rather, with high coverage of seven simple inter-
ventions the burden of diarrhea could be greatly reduced
[2]. Prevention interventions include regular hand washing
with soap, improved access to clean water and sanitation
facilities, breastfeeding, routine vitamin A supplementa-
tion and rotavirus vaccination. New diarrhea treatment* Correspondence: cfwalker@jhsph.edu
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2014guidelines came out in 2004, introducing zinc supplemen-
tation and low osmolarity oral rehydration salts (ORS) for
the treatment of all diarrhea episodes [3]. Evaluating these
diarrhea management interventions within a broad child
health framework is critical if we are to continue to under-
stand where new programs are achieving success and where
some have failed to reach young children.
A rigorous prospective program evaluation includes
components of inputs, processes, outputs, outcomes and
impact [4], but often collecting quality data at each of these
levels while also collecting critical information with regard
to contextual variables is not fiscally feasible. Impact mea-
sures, such as reduction in diarrhea specific mortality or
stunting rates, are the most difficult to measure becauseoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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extremely large, even if it is anticipated that the targeted
program achieved a successful scale up. The Lives Saved
Tool (LiST) is a model used to calculate deaths averted or
lives saved by past interventions and for the purposes of
program planning when costly and time consuming impact
studies are not possible. In this paper we will review the
components of LiST that are critical for modeling diarrhea
mortality. We will explain how the model includes direct
and indirect effects on diarrhea mortality, sources for
current LiST estimates, and discuss the benefits and weak-
nesses of using LiST as an alternative to measured diarrhea
mortality. This is the first paper to describe the full LiST
model with regard to the complexity of diarrheal disease.
Discussion
Lives saved tool (LiST): background and history
The Lives Saved Tool (LiST) has been developed over
the past 10 years. The initial version of the software was
developed as part of the work for the Child Survival
Series published in Lancet in 2003 [5,6]. The purpose of
the program was to estimate the impact that scaling up
community-based interventions would have on under-
five mortality [7], with both a limited set of interventions
and outputs and very limited demographic capability.
Starting from this initial point the software was expanded
first to handle a new set of interventions that focused
more on facility-based care with the primary impact being
on neonatal mortality [8,9]. The model was then improved
to handle populations and cohorts and to include wasting
and stunting as risk factors as part of the work for the
Lancet Nutrition Series [10]. This further development of
the software was supported by the Bill & Melinda Gates
Foundation as part of the work of the Child Health and
Epidemiology Reference Group (CHERG). The software
was then shifted into the free and publicly available
Spectrum software package, to take advantage of the
demographic capabilities in that software and to provide
links to the AIDS Impact Model module that had been de-
veloped to estimate the impact of HIV/AIDs [11]. Since
that time, LiST has expanded its scope to look at the im-
pact of interventions on birth outcomes and stillbirths
[12], maternal mortality, and incidence of pneumonia and
diarrhea [13] as well as neonatal and child mortality.
Theoretical approach and basic modeling structure of LiST
LiST is characterized as a linear, mathematical model
that is deterministic [14]. It describes fixed relationships
between inputs and outputs that will produce the same
outputs each time one runs the model. In LiST the pri-
mary inputs are coverage of interventions and the out-
puts are changes in population level of risk factors
(such as wasting or stunting rates, birth outcomes, such as
prematurity or size at birth) and cause-specific mortality(neonatal, child mortality 1 to 59 months, maternal
mortality and stillbirths). The relationship between an
input (change in intervention coverage) with one or
more outputs is specified in terms of the effectiveness
of the intervention in reducing the probability of that
outcome. The outcome can be cause-specific mortality or a
risk factor. The primary underlying assumption in LiST is
that mortality rates and cause of death structure will
not change except in response to changes in coverage
of interventions. The assumption is that changes in dis-
tal variables, such as increase in per capita income or
mothers’ education, will decrease cause-specific mortality,
such as diarrhea mortality, by increasing coverage of inter-
ventions or reducing risk factors, such as increased rates
of exclusive breastfeeding.
Currently there are around 67 interventions in LiST,
although the number of interventions that are in LiST is
growing as new interventions are added. These interven-
tions have an impact on stillbirths, neonatal mortality,
mortality in children 1 to 59 months, maternal mortality
or risk factors within the model. Interventions can be
linked to multiple causes of death and risk factors. A key
feature of LiST is that it allows one to look at the impact
of scaling up coverage of multiple interventions simul-
taneously, instead of a single intervention and one cause
as is done in many natural history models. As an ex-
ample, this has been done for the scale up of prevention
and treatment interventions for diarrhea mortality [15].
Authors demonstrated that diarrhea mortality could be
reduced by at least 78% with ambitious, yet feasible, im-
provements in the coverage of all key diarrhea preven-
tion and treatment interventions by 2015 in 68 priority
low- and middle-income countries.
There are structural features about the model that
must be considered in order to estimate the impact of
scaling up coverage of multiple diarrhea interventions
and changes in risk factors on diarrhea mortality. First,
the effectiveness or efficacy of an intervention must be
described in terms of reduction in cause-specific mortal-
ity rather than in overall mortality. For example, the
effect size of vitamin A supplementation is usually cited as
it relates to a reduction in all-cause mortality, but LiST re-
quires a reduction in all-cause mortality be converted to a
reduction in cause-specific mortality. For Vitamin A, this
means that the reduction in mortality must be attributable
to one or more causes of death, such as diarrhea deaths,
and each requires an accompanying effect size. With cause-
specific estimates of efficacy we can then compute the com-
bined impact of interventions.
Within LiST, efficacy of an intervention is defined in
terms of the reduction of a cause of death or risk factor.
When there is a single intervention the calculation of
impact is simple as one has change in coverage times
the efficacy of the intervention and this is applied to the
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have 10,000 diarrhea deaths among children aged 1 to
59 months/year and we introduce a new vaccine that is
50% effective in reducing diarrhea mortality we can esti-
mate the number of lives we would save. If coverage
were to reach 50% of children we would then reduce
diarrhea mortality to 7,500 (10,000 – (10,000 *0.5 * 0.5))
diarrhea deaths/year. When there is a second or a third
intervention, the same approach is followed except that
the second diarrhea intervention would be applied to
the residual diarrhea deaths. So, if a second new diarrhea
intervention is also 50% effective and coverage reaches
50% we would further reduce diarrhea mortality to 5,626
deaths/year. By using cause-specific efficacy and applying
each intervention to the residual deaths after the previ-
ous intervention we ensure that we are not double
counting the impact of interventions. Within LiST users
are able to include any number of prevention and treat-
ment interventions to model real changes in coverage or
to create new scenarios. Any time multiple interventions
are being modeled at one time, the preventive interventions
will act on diarrhea mortality first. Treatment interventions
will then prevent the residual of deaths as was described
above. When a user is interested in a total number of
deaths prevented by a package of interventions, this differ-
entiation occurs in the model (that is, behind the scenes)
and is not important because deaths are not attributable to
one specific intervention in the output. However, if a user is
interested in intervention specific deaths prevented, it may
be necessary to run LiST several times isolating individual
interventions in addition to a package of interventions
to understand more fully the potential contribution of
unique interventions.
Modeling reduction in diarrhea mortality using LiST
Diarrhea mortality is one of the most complex causes of
death to be modeled within LiST. The complexity is
driven by the combination of direct prevention and treat-
ment interventions as well as interventions that operate
indirectly via the reduction in risk factors, such as stunting
and wasting. Figure 1 illustrates the interventions that
have direct impacts on diarrhea mortality within LiST. For
prevention, they include: rotavirus vaccine; vitamin A sup-
plementation for children 6 to 59 months of age every six
months; preventive zinc supplementation; age appropriate
breastfeeding; and water, sanitation, and hygiene interven-
tions at the individual and household levels.
Each of these interventions directly prevents a propor-
tion of diarrhea deaths. For example, the effectiveness
estimate for zinc for the treatment of diarrhea is 23%. In
LiST to achieve a reduction in mortality, the effect size
is multiplied by the coverage and assumes that all other
interventions are kept constant. Thus, at 100% coverage,
zinc treatment could prevent 23% of current diarrheadeaths among children 1 to 59 months of age. If cover-
age were halved to 50%, the deaths prevented would also
be reduced by 50%. The sources of data for the gener-
ation of effect sizes for all interventions are discussed
below and all point estimates are provided in a detailed
Additional file 1. Appropriate breastfeeding is slightly
different than the aforementioned preventive interven-
tions included in LiST. Breastfeeding is included in two
parts, the action of breastfeeding and the intervention of
breastfeeding promotion. With regard to mortality, the
lack of appropriate breastfeeding can be modeled as a
risk factor. In LiST, the proportion of children receiving
appropriate breastfeeding can be directly changed over
time (to see the impact of changing breastfeeding rates)
or it can be modeled as a risk factor that changes with
the intervention of breastfeeding promotion shifting
rates of breastfeeding practices.
There are three interventions for the treatment of
diarrhea: zinc treatment, ORS, and antibiotics for dysen-
tery that directly impact diarrhea mortality in the model.
One important concept in LiST is that some interven-
tions are able to act on diarrhea deaths that are caused
by a specific etiological agent or agents. This is the case
of antibiotics for the treatment of dysentery. In LiST, an-
tibiotics are only able to prevent dysentery deaths and,
thus, only prevent that proportion of all diarrhea deaths.
This is termed the ‘affected fraction’ in LiST. Details of
each intervention are explained in subsequent sections.
Most causes of death in LiST do not include disease
incidence in the pathway because the primary purpose
of LiST is to model mortality reductions. However, diar-
rhea incidence is critical in the stunting/mortality path-
way so it is included in the LiST tool. Figure 2 illustrates
the interventions that impact diarrhea incidence. Given
that diarrhea incidence is in LiST in addition to diarrhea
mortality, a user could model changes in diarrhea inci-
dence as a result of the scale up of diarrhea prevention
and treatment interventions, but this is rarely of interest
when using LiST.
Figure 3 illustrates how the preventive interventions
that decrease diarrhea incidence, decrease stunting,
which then decreases overall diarrhea mortality during
the post neonatal period. For these interventions, LiST
includes values for the effectiveness of the intervention
on direct mortality reduction and the reduction on
diarrhea incidence. The impact of diarrhea incidence
on stunting is then calculated based on data from a
pooled analysis of several large cohort datasets [16]. Finally,
the risk of stunting on diarrhea mortality is modeled using
data from cohort and interventions studies that observed
an increased risk of diarrhea mortality as the degree of
stunting increases [17].
Lastly, there are several interventions that can be de-
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Figure 1 Interventions with direct impact on diarrhea mortality. Green shaded boxes indicate prevention interventions. Blue shaded boxes
indicate treatment interventions. Peach and grey boxes indicate interventions that have an impact on diarrhea via a risk factor pathway.
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tional age (SGA). Both preterm delivery and SGA are risk
factors for stunting and are thus included in the complete
set of interventions impacting diarrhea mortality in
Figure 4. Wasting is also a risk factor for diarrhea mor-
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Figure 2 Interventions impact direct mortality and diarrhea incidence
boxes indicate treatment interventions. Peach and grey boxes indicate inteof wasting will also contribute to a reduction in diar-
rhea mortality. This last group of interventions is not
typically thought of as diarrhea-specific prevention and
treatment interventions and further discussion of these
interventions is beyond the scope of this report. They
are included in Additional file 1.ORS 
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Figure 3 Interventions impact diarrhea directly and via the stunting pathway. Green shaded boxes indicate prevention interventions.
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Figure 4 Complete set of interventions impacting diarrhea mortality. Green shaded boxes indicate preventive interventions. Blue shaded
boxes indicate treatment interventions. Peach and grey boxes indicate interventions via a risk factor pathway.
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Table 1 Illustration of the effect of breastfeeding promotion
on the proportion of infants breastfed, by degree of
breastfeeding and age
0 to 1 month 1 to 5 months
Breastfeeding Baseline After promotion Breastfeeding Baseline
Exclusive 62.0% 69.6% 40.2% 54.5%
Predominant 25.0% 20.0% 29.1% 22.1%
Partial 10.3% 8.2% 29.2% 22.2%
None 2.7% 2.2% 1.5% 1.1%
Breastfeeding promotion scaled from 40% to 80% of pregnant women.
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Impact of breastfeeding on diarrhea mortality
Breastfeeding is the best source of nutrition for young
infants and an important tool in the prevention of diar-
rhea morbidity and mortality. The current WHO recom-
mendations are for exclusive breastfeeding from birth
until six month of age and continued breastfeeding until
two years of age [18]. The LiST tool includes breastfeeding
as a critical tool for the prevention of diarrhea morbidity
and mortality, quantifying the increased risk of suboptimal
feeding from 0 to 5 months, 6 to 11 months and 12 to 23
months of age. The effect sizes included in the LiST tool
are presented in Additional file 1. To generate these esti-
mates, Lamberti and colleagues conducted a systematic
literature review to identify intervention and observational
cohort studies. Few prospective studies are designed and
powered to detect differences in diarrhea mortality so the
authors included outcomes of incidence and severe dis-
ease to provide additional evidence. Assessing the effect
size across disease severity is beneficial because it allows
for a more complete picture of the evidence even if all es-
timates are not included in the final LiST tool. There are
two pathways by which breastfeeding can decrease the risk
of mortality in the LiST model. The first is by directly
lowering the risk of direct mortality, which is likely
due to a reduction in the risk of having a severe and/or
prolonged episode of diarrhea. The second is by decreas-
ing diarrhea incidence, which has an indirect effect on
diarrhea mortality.
When reviewing the evidence of association between
lack of breastfeeding and risk of disease or mortality it is
important to minimize the bias of reverse causality. This
occurs when the mother stops breastfeeding or intro-
duces other liquids or foods to the child in response to
an illness, such as diarrhea. This bias can be minimized
by including only prospective studies in the generation
of effect sizes as was done in Lamberti et al. [18].
Impact of breastfeeding promotion on breastfeeding patterns
Community or hospital-based interventions, such as
education and counseling, are needed to increase breast-
feeding rates. LiST allows users to evaluate the impact of
changing breastfeeding patterns on mortality in two
ways, through increasing the coverage of breastfeeding
promotion or by directly changing the breastfeeding pat-
terns in four age periods. For LiST, there have been reviews
that estimated the impact of breastfeeding promotion on
adoption of correct breastfeeding patterns [19,20]. The final
effect size generated by these reviews included all studies
regardless of study quality and did not attempt to adjust for
or categorize the results according to the intensity of the
intervention delivered. For a user looking to measure the
effect of breastfeeding promotion on diarrhea morbidity
and/or mortality, additional knowledge about the setting,dose and measured impact on breastfeeding rates may
improve the estimate.
The estimated relative risk of appropriate breastfeeding
given breastfeeding promotion is used to estimate the
change in appropriate breastfeeding in each of the periods.
For the time periods 0 to 1 month and 1 to 5 months the
optimal breastfeeding is exclusive breastfeeding and for
the periods of 6 to 11 months and 12 to 23 months the
optimal breastfeeding is any/continued breastfeeding. For
the period under six months, the remaining sub-optimal
breastfeeding is distributed among the three sub-optimal
categories (predominate, partial and none) based on their
proportions prior to breastfeeding promotion scale up. An
example of how breastfeeding promotion can change the
proportion of babies receiving different degrees of breast-
feeding is provided in Table 1.
In addition to using breastfeeding promotion to alter
breastfeeding patterns, users can also directly change the
breastfeeding rates. This allows users to estimate the opti-
mal impact of improving breastfeeding as well as allowing
users to look at historical patterns to estimate the impact
of changes in breastfeeding on under-five mortality.
Impact of rotavirus vaccine on diarrhea mortality
Rotavirus is the leading cause of diarrhea mortality
among children under five years of age [21]. In 2009,
data from new studies in Asia and Africa were released
and the World Health Organization began recommend-
ing rotavirus vaccine for routine vaccination of infants
in all countries [22]. The current estimate used in the
LiST model includes a combined effect size for the two
oral, live, attenuated vaccines on the market and avail-
able as of January 2009, Rotarix (GlaxoSmithKline) and
RotaTeq (Merck & Co, Inc.) [23]. The most recent re-
view of the evidence included data from four new stud-
ies in Asia and sub-Saharan Africa. The LiST model
includes regional specific effect sizes. The original rota-
virus vaccine trials did not measure diarrhea mortality;
the most severe outcome has been severe rotavirus mor-
bidity, which is thus used as a proxy for mortality in the
model [23]. In addition, rotavirus vaccine reduces rota-
virus diarrhea incidence by 50% [24].
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virus differs by setting. Ideally, these measures would be
available at the country level, but this is rarely the case.
As more data become available at the regional or coun-
try level, these details can be fed into LiST and continu-
ous updates generated. For now, LiST uses regional
estimates but these can be updated with country-specific
information when available. The proportion of diarrhea
deaths attributed to rotavirus is used in LiST as the affected
fraction. Country level data with regard to rotavirus strains
could also provide additional data to further refine the esti-
mate of effectiveness of the vaccine or the pathogenicity of
the specific strain of rotavirus circulating in a specific popu-
lation, but these data are rarely available.
The variation in efficacy of the vaccine by region is im-
portant but additional data with regard to understanding
what fraction of the observed variation is due to differ-
ences in strains versus host response will be critical to
continue to improve upon current vaccine efficacy and
the LiST effect size estimates. Some have speculated that
vaccine efficacy might be influenced by such things as
breastfeeding status, nutritional status, environmental
enteropathy (that is, subclinical infections), or other
environmental factors but additional research is needed to
understand more fully how, and if, these factors may or
may not be important [25].
LiST does not include default measures of herd im-
munity. LiST, as a model, is able to include the effect of
herd immunity for any vaccine or intervention where
herd immunity is important. At the present time, effect
sizes for herd immunity have not been generated but ex-
perts are currently working on finalizing these estimates
for rotavirus vaccine. When these data become available
the overall effect of rotavirus vaccine in LiST will be
changed to include herd immunity.
Impact of water, sanitation, and hygiene interventions for
the prevention of diarrhea on diarrhea mortality
Water, sanitation, and hygiene (WASH) interventions in-
clude a wide spectrum of interventions, ranging from indi-
vidual level behavior modification, such as handwashing
promotion, to large-scale infrastructure interventions, such
as the provision of piped water into the home. LiST includes
the following interventions for the prevention of diarrhea:
promotion of handwashing with soap; having access to an
improved water source; a water connection in the home;
improved sanitation source (that is, latrine/toilet); and the
hygienic disposal of children’s stools. By nature, WASH
interventions do not lend themselves well to blinded
study designs and it is extremely difficult to randomize
individuals in WASH studies; thus, there are no gold
standard studies for which to determine effect sizes.
Many studies are observational designs and in these studies
there is often inadequate controlling for confounding [26].In addition, many WASH studies were never designed to
measure reductions in severe morbidity or mortality and
WASH interventions are often presented in a package such
that the effect of a group of interventions is being measured
and thus attributing the effect of one intervention on any
morbidity reduction is impossible.
Handwashing with soap is an important intervention
for the prevention of diarrhea included in LiST. How-
ever, measuring this intervention is extremely difficult.
Blinded studies cannot be done and non-blinded studies
are subject to the placebo effect when asking caregivers
about diarrhea incidence. By being part of a handwash-
ing study, families may have adapted other more sanitary
behaviors in the home and may also recall diarrhea less
frequently, convinced that better habits have changed
diarrhea incidence. Summary measures of water quality
interventions are difficult to calculate because of the diver-
sity of settings which directly influences the quality of the
baseline water and the number of different kinds of inter-
ventions from home-based and home-made improved
water solutions, such as filters, to commercial purifica-
tion systems or tablets and the ideal scenario of piped
clean drinking water. Waste disposal ideally occurs in
an appropriately designed and maintained latrine or
toilet, but these are still not accessible to many of the
rural poor. Large randomized studies are rare due to
the cost of building and maintaining latrines and toilets
for large sample sizes and observational studies cannot
fully control for clear differences in families that are able
and willing to invest in a latrine versus those that are not
able or chose not to.
Although the available literature does not provide ideal
study designs and the overall quality of the data are very
weak for some interventions, the consensus is that WASH
interventions are important for the prevention of diarrhea
[26]. These limitations should be considered when asses-
sing the effect sizes included in LiST and might be further
tailored when considering data from any one particular
country. In the recent review by Cairncross et al. [26], the
authors point out the limitations of the available data and
encourage users of LiST to exercise caution with regard to
the certainty of the size of the effect.
Impact of routine vitamin A supplementation on
diarrhea mortality
Vitamin A supplementation every six months for the
prevention of all-cause mortality is recommended for
children six months to five years of age. In the recent
review by Imdad et al., for use in LiST, the authors in-
cluded both individual and cluster randomized trials
[27]. Vitamin A supplementation has a direct effect on
diarrhea mortality in LiST by reducing the mortality risk in
vitamin A deficient children. Vitamin A reduces both the
severity of disease (that is, the direct effect on mortality)
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on mortality) and both are included in LiST [13]. Most
vitamin A studies were conducted more than 20 years
ago in settings known to be vitamin A deficient. The
proportion of children who are vitamin A deficient and,
thus, who would benefit from vitamin A supplementation
varies by region and is represented in LiST by regional
specific affected fractions [13]. New data primarily gener-
ated from neonatal studies have suggested that there may
be differences in effect size between Asia and Africa,
but in a subgroup analysis of studies included in current
estimates for children 6 to 59 months, there is not a sta-
tistically significant difference [27]. Coverage estimates
need to reflect this twice yearly supplementation recom-
mendation for valid use in LiST.
LiST does not currently include an estimate for vitamin
A supplementation on diarrhea mortality associated with
neonatal vitamin A supplementation. As new studies are
conducted and the evidence base grows, this intervention
will be re-considered for inclusion in LiST. At present
there is not enough evidence to suggest a beneficial effect
of vitamin A in this age group [27].Impact of preventive zinc supplementation on
diarrhea mortality
Routine zinc supplementation has the ability to reduce
diarrhea morbidity and mortality especially among children
who are zinc deficient [28]. While it is not yet a widely used
intervention and not an intervention included in routine
Demographic and Health Surveys (DHS) and Multiple
Indicator Cluster Surveys (MICS), zinc supplementation
for children one- to four-years-old is included in LiST.
The effect sizes in LiST are based on a systematic review
published as part of the LiST review supplements with
later adjustments made by the Lancet Nutrition Series
Working Group to include more tailored estimates of
morbidity and mortality reduction based on the percent
of the population at risk for zinc deficiency [28-30].
Routine zinc supplementation now operates in LiST in
the same way as vitamin A, that is through an affected
fraction, the percent of the population of children in the
targeted age group at risk of deficiency. This improve-
ment will be important and will ensure that the esti-
mates of the effect on morbidity and mortality remain
relevant as the background nutritional status of the
population under five years of age continues to improve.
Within LiST this remains an intervention that is usually
included only in hypothetical scale-up models of lives
that could be saved because very few places have wide-
spread routine supplementation programs in place.
2Interventions, such as daily multiple micronutrient
sprinkles containing zinc, may or may not have similar
effects on diarrhea morbidity and mortality and, thus,cannot be interchanged with this intervention until the
appropriate level of evidence is generated.
Impact of zinc supplementation for the treatment of
diarrhea on diarrhea mortality
Zinc for the treatment of diarrhea has been recom-
mended by WHO and UNICEF as an adjunct treatment
for all episodes of diarrhea among children under five
years of age since 2004 [3]. The randomized placebo
controlled trials that generated the efficacy data which
led to this recommendation were not designed or pow-
ered to detect differences in all-cause or cause-specific
mortality; rather, these were treatment studies designed
to measure the benefit of zinc on the duration and se-
verity of the treated episode [31]. The systematic review
that generated the evidence for the estimate currently
included in LiST includes data from a literature review
that included studies published from 1980 to 2009 [31].
A new review was conducted recently including studies
published through 2012; this review also includes studies
published in Chinese that had not previously been in-
cluded in any review [32]. The results of this review
will provide updated estimates for outcomes, such as
the effect of zinc on diarrhea duration and severity, but
will not change the LiST estimate because none of the
new studies were effectiveness studies and they did not
include the outcome of hospitalizations, which is what
current LiST estimates are based on.
To date, there has been one study published that found
an observed 66% (95% confidence interval (CI) −37, 96%)
reduction in diarrhea specific mortality, but even this large
community based study was not powered to detect cause-
specific reduction in mortality [33]. Four studies report re-
ductions in all cause mortality. Although the results of the
pooled analysis produced a statistically significant reduc-
tion (46%, 95% CI: 12% to 68%) [31], it is important to
note that these studies were not designed to measure the
effect of zinc on mortality [33-36]. There were also very
few deaths in these four studies. The rules of the LiST tool
dictate that when there are fewer than 50 events for a
given outcome, the effect size of the intervention on a less
severe outcome should also be considered and the smal-
lest effect size (that is, the most conservative estimate)
used [37]. In the case of zinc supplementation, the reduc-
tion in hospitalizations was 23% and there were at least 50
hospitalizations overall among the studies that measured
hospitalization so this estimate was then adapted by LiST
for the effect size of zinc [31].
In the case of zinc, the 23% reduction in hospitaliza-
tions can be argued to be a very conservative effect size
estimate as it is based on community-based intervention
studies and measured reductions in hospitalizations in
the community; however, in these studies coverage did
not reach 100%. In Bangladesh, coverage reached more
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60% [38]. It is important to note that in these two stud-
ies, the recommended duration of treatment was 14
days; the WHO/UNICEF recommendation is 10 to 14
days of zinc. In India, 61.7% of children received the
full 14 days of treatment [38]. In Bangladesh the mean
course of treatment was seven days [33]. Both studies
also promoted ORS and observed increases in ORS use
rates in the villages that received zinc; thus, it is diffi-
cult to isolate the effect of zinc alone in these treat-
ment studies. The 23% reduction in mortality that is
used in LiST for the effectiveness of zinc treatment is
consistent with the observed 25% reduction in pro-
longed diarrhea based on efficacy studies which were all
individually randomized, unlike the cluster randomization
in the effectiveness studies [31]. Some studies have shown
a reduction in diarrhea incidence in the two to three
months following the treated episode, but this is not
included in LiST [39].
Impact of oral rehydration salts for the prevention and
treatment of dehydration on diarrhea mortality
ORS has been the cornerstone of diarrhea treatment
since the 1970s, preventing and treating dehydration.
In 2004, WHO updated the recommendation to a new
lower osmolarity version of ORS [40,41]. Low osmolar-
ity ORS prevents and treats dehydration more effect-
ively by decreasing the incidence of vomiting, lowering
stool output, and decreasing the likelihood of needing
intravenous therapy (IV) [40]. The early studies dem-
onstrating the efficacy of ORS were controlled trials
assessing ORS versus IV therapy as it would have been
unethical to include a placebo for the treatment of de-
hydration [42]. After efficacy was proved, researchers
moved to community-based intervention studies intro-
ducing ORS also as a preventive tool for dehydration
[42]. These studies often compared more aggressive
delivery strategies with routine delivery and measured
differences in coverage to determine the added effect
of ORS on mortality.
Past Cochrane reviews included the outcome of treat-
ment failure for original ORS, low osmolarity ORS, and
a comparison of rice-based versus glucose-based ORS
[40,43,44]. All Cochrane reviews included studies con-
ducted in hospital and clinical settings. ORS, as an
intervention in LiST, is a community-based intervention
for the prevention of diarrhea mortality in the community
and in clinical settings. Munos et al. conducted a new
systematic review including many diverse study designs
(quasi-experimental, pre/post and observational) and
studies conducted in the community as well as in hospital/
clinical settings [42]. For the three large community-based
studies that assessed diarrhea mortality, the reported reduc-
tion in mortality is associated with an achieved coveragerate [45-47]. For the purposes of calculating the potential
reduction in diarrhea mortality, the authors assumed a
linear trend between the relative reduction in mortality
and achieved coverage, such that if ORS reduces diarrhea
mortality by 69% at 74% coverage, then ORS would reduce
mortality by 93% at 100% coverage [42]. It is important to
note that community-based studies have some level of
coverage of ORS in control communities, which is not
taken into account, and thus this estimate is a conserva-
tive estimate and may overestimate the true coverage
needed to reach the estimated mortality reduction.
LiST does not include other strategies for the prevention
of dehydration, such as the provision of recommended
home fluids (RHF). Providing fluids, other than ORS,
for the prevention of dehydration became popular in
the 1980s with a movement for home-based management
without having to purchase any outside therapy. Sugar-
salt-solution, the closest home-made solution to ORS, was
tested in hospitals and found efficacious [42]. That is, if
prepared in a hospital setting it could be used successfully
but it did not go through testing in community settings,
the very setting where it is intended for use. Other fluids
were meant for the early prevention of dehydration in the
home and were never meant for the treatment of dehydra-
tion and never formally tested.
Impact of antibiotics for the treatment of dysentery on
diarrhea mortality
The selective use of antibiotics for the treatment of
dysentery is a key component of diarrhea management
[3]. In low- and middle-income countries, dysentery and,
more specifically, dysentery deaths are typically caused by
Shigella [21,48,49]. Beyond treating the episode of dysen-
tery, antibiotic treatment is important in decreasing the
bacterial load in excrement and then decreasing the risk of
fecal-oral transmission in the household and community
[50]. LiST includes estimates of effectiveness of the WHO-
recommended antibiotics (that is, ciprofloxacin, ceftriaxone
and pivmecillinam) on dysentery. The LiST estimate of
99% reflects the rate at which clinical signs and symp-
toms of Shigella were eliminated [51]. This estimate is
in line with estimates of bacteriologic failure rates of 99%
to 100% [51,52]. The LiST estimate operates through
an affected fraction which, in this case, is 3.9% (that is,
the percent of diarrhea deaths attributable to Shigella)
[21]. Thus, in LiST if the coverage of antibiotics for the
treatment of dysentery were to be 100%, 3.86% of diarrhea
deaths (that is, 99% of 3.9%) would be prevented.
Antibiotics are widely and inappropriately used for the
treatment of routine acute diarrhea in many countries.
Anti-diarrheals are also common. The coverage of anti-
biotics is difficult to trace in coverage surveys because
differentiating between antibiotics and anti-diarrheals is
difficult. Where the caregiver is no longer in possession
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antibiotics and anti-diarrheals are available, the caregiver is
often unable to remember or correctly identify which drug
was given to the child. For these reasons, accurately meas-
uring coverage of antibiotics is challenging [53].
Improving data inputs will improve LiST outputs
Diarrhea etiology
Childhood infectious diarrhea is typically caused by viruses,
bacteria and parasites. The etiology of acute diarrhea has
been widely studied among incident cases yet, in low- and
middle-income countries, the causes of most cases of acute
diarrhea are never investigated as part of routine treatment
protocols. Estimates of the pathogen specific causes of diar-
rhea deaths are extrapolated from hospitalized cases be-
cause global data for pathogen specific cause of death do
not exist for low- and middle-income countries [21]. For
these reasons, in LiST very few diarrhea interventions are
diarrhea pathogen-specific. LiST does incorporate an esti-
mate for the proportion of diarrhea deaths attributable to
rotavirus; the rotavirus vaccine prevents deaths from within
this affected fraction. LiST also incorporates an estimate for
the fraction of deaths attributable to dysentery, clinically
recognized as blood in the stool. The scale up of antibiotic
treatment for dysentery prevents deaths from within this af-
fected fraction of all diarrhea deaths. As new interventions
are made available, for instance, a program to include chol-
era vaccine, LiST is able to incorporate etiologic specific
mortality by including an estimate of the proportion of
deaths attributable to a specific etiology. Although all eti-
ologies are not currently included in LiST, recent estimates
for the most important causes of diarrhea are available and
could be included as needed [21].
New interventions
LiST also has a feature that allows users to add new in-
terventions into the model. To do this, users must spe-
cify the links between the new interventions and
outcomes (risk factors or causes of mortality) as well as
the efficacy of the intervention on the outcomes to
which it has been linked. Also for diarrhea, LiST has
two additional vaccines (called vaccine B and vaccine
C) included as ‘dummy vaccines’ for testing the pos-
sible impact of new vaccines. Users can link one of
these ‘dummy vaccines’ to etiologically specific causes of
diarrhea mortality and morbidity. In the standard ver-
sion of LiST, the links and efficacy values for these two
vaccines are left blank, but the user can define the link-
ages and efficacy values. These extra vaccines were
added to the model as there has been much work in the
development of vaccines for diarrhea for enterotoxigenic
Escherichia coli (ETEC) and Shigella. This feature also
allows a user to estimate the impact of cholera vaccines
if that vaccine is used in a country.Accuracy of LiST estimates and possible limitations to
the model
There has been extensive work comparing the estimates
that come from LiST to measured changes in intervention
coverage and mortality. Several studies have compared
measured changes in mortality to LiST estimates of
mortality change looking at different sets of interventions
in different countries. For example, one study compared
LiST estimates to measured reduction in neonatal mortal-
ity in community trials in South Asia [54]. Another study
looked at community trials that focused on the scale up
and use of insecticide treated nets (ITNs) in sub-Saharan
Africa [55]. A third compared measured and estimated
mortality for a community trial in Mozambique [56].
In all of these studies there was close agreement between
the estimates of mortality from LiST based on coverage
changes and the measured reductions in mortality.
Additional studies doing comparisons of LiST have been
published in the LiST journal supplements [57-59].
While the comparison work has generally found good
agreement between the LiST estimates and measured
mortality reduction, there are issues or circumstance
that could make the LiST estimates less accurate or the
model less robust. These issues generally fall into two
categories; one related to data availability and the second
to the general structure and assumptions of the model.
These issues will be discussed below.
One of the major issues with regard to accuracy of the
LiST model is the availability of data on coverage of
interventions. While most low- and middle-income
countries do have periodic surveys that measure cover-
age of key interventions for maternal and child health
(as well as for risk factors such as breastfeeding pat-
terns, stunting and wasting) these surveys often occur
only every three to five years. This means that for many
countries when we build a baseline, the coverage data
are not current. A second issue related to coverage is
that while survey questions yield the base data we have
on coverage of interventions for most low- and middle-
income countries, the surveys themselves do not neces-
sarily provide highly accurate measures of coverage of
many interventions. In May 2013, PLoS Medicine pub-
lished a series of papers that evaluated how well house-
hold surveys, such as MICS and DHS, measured coverage
of selected key interventions for maternal and child health
[60]. These studies found that surveys often do not pro-
vide highly accurate estimates of coverage, especially for
treatment interventions, such as antibiotics for pneumonia
and the treatment of diarrhea [53,61]. Finally, there are in-
terventions used in LiST where we have no reliable source
of coverage information from the major household surveys.
For example, for many of the interventions during antennal
care and child birth, surveys only capture the number of
antenatal visits, or locations and type of service provided
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services (for example, detection and treatment of syph-
ilis or diabetes for pregnant women; availability of core
services that comprise basic or emergency obstetric
care during child birth). Instead in LiST we used data
from a small set of studies to estimate coverage change
of the actual interventions as they relate to the indica-
tors measured in surveys (for example, four antenatal
visits, skilled birth attendant, and institutional delivery).
For diarrhea interventions, the intervention for which
we have the poorest measures of coverage is hand wash-
ing with soap, as reported behaviors are often unreliable
and direct observation is very difficult; thus, this meas-
ure is particularly problematic [26].
In terms of limitations or restrictions to the wide-spread
appropriate use of LiST in modeling mortality reduction
there are two primary issues that have been raised by re-
viewers of papers using LiST to model mortality reductions.
These are the inability of LiST to capture secondary effects
of an intervention on overall mortality (as LiST models
effects of interventions on cause-specific mortality) and the
assumption that coverage measures of interventions are in-
dependent. We will discuss these issues separately below.
The idea of secondary effects of interventions not
captured in LiST is primarily based on the idea that if
one reduces the incidence and mortality of one disease
due to an intervention the reduction in one disease will
result in the child being healthier and less vulnerable
to the exposure of a second disease. For example with
diarrhea, people have argued that as we have reduced
the incidence of measles due to the high coverage of
measles vaccine, measles as a diarrhea risk factor has
been drastically reduced and, thus, children are less
likely to develop diarrhea and for those who have diarrhea
less likely to die [62]. Currently, LiST does not include
estimates for secondary effects. For example, a measles
vaccine reduces measles incidence and mortality, but
has no effect on diarrhea deaths. Of course, conceptually
this could be added to the model quite easily, as interven-
tions can have effects on more than one cause of death.
However, to date most intervention reviews have not found
a significant effect of the secondary causes of mortality.
One of the reasons that some argue that LiST is missing
the significant impact of interventions via secondary effects
is that trials that have looked at the impact of an inter-
vention on all-cause mortality often find larger effects
on all-cause mortality than would be expected if there
were no secondary effects. For example, one of the early
insecticide-treated bed net trials found a more than 50%
reduction in all-cause mortality among children when
the estimated proportions of deaths due to malaria were
estimated to be around 40%. The same comparisons have
been used to also argue that LiST use of efficacy values
linked to cause-specific mortality has under-estimatedthe overall impact of interventions, such as vaccines
and vitamin A supplementation [63]. However, when
data have been available to compare LiST estimates that do
not include these secondary effects to measured all-cause
mortality, there has been little evidence that LiST systemat-
ically under-estimates the effects. For more details on this
see the analyses done by Larson et al. [55].
Another possible issue with the structure of LiST is
that it assumes that coverage estimates of interventions,
when scaled up, are independent. Basically, this assumes
that there is not a large section of the population that
has little or no chance of getting any interventions.
Theoretically, if coverage of one intervention was
strongly associated with coverage of others (and clearly
there is some association) then LiST could produce
biased estimates of the impact of scaling up coverage at
the population level. Victora and colleagues addressed the
theoretical and actual impact of equity of coverage [64]. In
this simulation the authors showed that there was a po-
tential and sizable bias with LiST estimates if coverage of
interventions were strongly correlated. However, the au-
thors also estimated the observed correlations between in-
terventions in a set of low- and middle-income countries
and found that the degree of correlation of intervention
coverage was not sufficient to lead to a sizable bias in LiST
estimates of the impact of interventions.
Using LiST as a tool within a comprehensive
program evaluation
Within the scope of program evaluation, donors or policy
makers are often concerned about whether or not a pro-
gram has had an impact, that is, has there been a measur-
able change on mortality or on nutritional status and can
this impact, if any, be attributable to a specific program.
LiST relies on accurate measurements of coverage and
with these has been shown to produce precise measures
of cause-specific mortality reduction [54,65]. However,
measuring coverage and modeling its impact on mortality
is only one key component for a complete program evalu-
ation. Bryce et al. have published a common evaluation
framework that clearly lays out the many components of a
complete program evaluation highlighting the leanings that
are needed at multiple stages [4]. A complete evaluation
is able to capture data about inputs, processes and out-
puts, not just outcomes and impact. LiST does not have
the capacity for describing why coverage of a certain
intervention increased or decreased beyond the indica-
tors that are measured routinely in surveys. Nor does it
have the ability to give guidance on ‘how’ coverage of an
intervention could be changed.
Summary
LiST is an excellent tool that has been used for many
years and has undergone numerous improvements over
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tinue to improve the model for years to come. LiST has
been tested many times to ensure the modeled mortality
estimates that it produces are valid and reproducible
[54,65]. The strength of LiST is dependent upon the
strength of the input data. LiST continues to update child
cause of death and overall mortality rates and includes the
most recent DHS and MICS coverage data for all included
child survival interventions. For time periods that do not
correspond to preset coverage surveys, LiST allows a user
to input different coverage estimates and, thus, LiST can
be used to model anticipated reductions in child mortality
if a given package of interventions were to be rolled out
for a specified project period. Ideally, every coverage sur-
vey rolled out as part of program evaluation would meas-
ure the coverage of all key child survival interventions
over the time period of interest. With these data, LiST is
able to account for changes in overall mortality or cause
of death structure and more precisely attribute any
changes in impact to the interventions in question.
Where limited coverage data are available, the user has
the ability to look at the impact of an isolated group of
interventions by keeping coverage estimates for other
interventions constant or can factor in past time trends to
include the influence of time trends of other interventions
but both of these methods introduce tremendous bias. LiST
is an effective tool for modeling diarrhea mortality and can
be a useful alternative to large and expensive mortality im-
pact studies. LiST will continue to evolve as additional data
are collected from trials and studies to better define cover-
age. Child mortality rates are rapidly declining and, thus,
the importance of tools such as LiST is becoming increas-
ingly important. Predicting the impact of interventions or
comparing the impact of more than one intervention with-
out having to wait for the results of large and expensive
mortality studies is critical to keep programs focused and
results oriented for continued reductions in diarrhea and




CI: confidence interval; DHS: Demographic and Health Surveys; LiST: Lives
Saved Tool; MICS: Multiple Indicator Cluster Survey; ORS: oral rehydration
salts; WASH: water, sanitation and hygiene.
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